| Type of medicine | A vasodilator antihypertensive medicine, called an endothelin receptor antagonist |
|---|---|
| Used for | Pulmonary arterial hypertension; to prevent skin ulcers in people with systemic sclerosis |
| Also called | Stayveer® |
| Available as | Tablets (62.5 mg and 125 mg) |
About bosentan
Bosentan, marketed as Stayveer, is a specialized medication classified as an endothelin receptor antagonist (ERA). It works by blocking the action of endothelin-1 (ET-1), a naturally occurring hormone that causes blood vessels to narrow. By preventing this narrowing, bosentan helps dilate blood vessels, reducing pressure and improving blood flow.
This drug is prescribed for two primary conditions. First, it treats pulmonary arterial hypertension (PAH), specifically in patients with WHO functional class III, to enhance exercise capacity and alleviate symptoms. PAH involves severe narrowing of the lung’s blood vessels, leading to high blood pressure in the pulmonary arteries, reduced oxygen supply, and symptoms like shortness of breath and fatigue. Clinical studies show bosentan improves the 6-minute walk distance (6MWD), a key measure of exercise capacity, when added to existing therapies.
Second, bosentan reduces the formation of new digital ulcers in patients with systemic sclerosis (scleroderma) who have ongoing digital ulcer disease. Systemic sclerosis causes vascular narrowing in the fingers and toes, resulting in painful ulcers. By improving circulation, bosentan prevents new ulcers from developing.
Stayveer is authorized by the European Medicines Agency (EMA) and is bioequivalent to Tracleer, leveraging the same scientific data through informed consent. Treatment must be initiated and supervised by a physician experienced in PAH or systemic sclerosis management. Patients receive a Patient Alert Card highlighting critical safety information, including liver monitoring and contraception requirements.
Bosentan is available in 62.5 mg and 125 mg film-coated tablets, orange-white, oval, biconvex, debossed with ‘125’ on one side for the higher dose. Tablets are swallowed whole with water, morning and evening, with or without food.
Key facts
- Bosentan is also known as Stayveer® or previously Tracleer.
- It targets PAH in WHO class III (severe limitation during ordinary activity) and sometimes class II, including idiopathic, heritable, scleroderma-associated (without significant interstitial lung disease), and congenital shunt-related cases like Eisenmenger’s physiology.
- For systemic sclerosis, it specifically lowers the rate of new digital ulcers.
- Dosage starts at 62.5 mg twice daily for 4 weeks, then 125 mg twice daily maintenance.
- Strict contraception is mandatory for women of childbearing potential due to teratogenic risks.
- Regular liver function tests (LFTs) and blood counts are required monthly.
- Not for use in pregnancy, breastfeeding, or severe liver impairment.
Before taking bosentan
Your doctor will review your medical history thoroughly before prescribing bosentan. Inform them if:
- You have liver problems or abnormal LFTs, as bosentan can cause serious liver injury, sometimes fatal.
- You have low blood pressure.
- You have porphyria, a rare blood disorder.
- You’ve had an allergic reaction to bosentan or similar drugs.
- You are pregnant, planning pregnancy, or breastfeeding – bosentan is contraindicated and highly teratogenic.
- You take other medications, including over-the-counter, herbal remedies, or drugs like sildenafil, warfarin, or hormonal contraceptives (bosentan reduces their efficacy).
For women who could become pregnant, effective contraception (e.g., intrauterine device or two barrier methods) is essential throughout treatment and for one month after stopping. Monthly pregnancy tests are required. Men should use condoms if their partner could become pregnant. A REMS-like program ensures compliance.
Blood tests for baseline liver enzymes (ALT/AST), hemoglobin, and hematocrit are mandatory before starting.
How to take bosentan
Follow your doctor’s instructions precisely. Bosentan is taken orally, twice daily (morning and evening), with or without food.
| Condition | Initial Dose (4 weeks) | Maintenance Dose |
|---|---|---|
| Adults (PAH or Systemic Sclerosis) | 62.5 mg twice daily | 125 mg twice daily |
| Children (PAH, ≥3 years) | Weight-based (typically 62.5 mg twice daily) | Up to 125 mg twice daily based on weight |
Swallow tablets whole with water. Do not chew or crush. Avoid swallowing the desiccant in bottles. For PAH, if no improvement after 8 weeks, continue up to 12 weeks; reassess if deterioration occurs. Same dosing for re-initiation after interruption.
Missed dose: Take as soon as remembered unless near next dose. Skip and resume schedule – never double dose.
In clinical trials (e.g., AC-052-351/352), bosentan added to standard therapy improved 6MWD by 30-50 meters vs. placebo after 16 weeks, with benefits seen from week 4.
Getting the most from your treatment
Attend all appointments for monitoring. Key checks include:
- Monthly blood tests for liver enzymes (ALT/AST >3x upper limit requires dose adjustment or discontinuation), anemia (hemoglobin drop), and fluid retention.
- Report symptoms like nausea, fever, jaundice, dark urine, fatigue, or abdominal pain immediately – signs of liver issues.
- Monitor weight for edema, especially with heart failure.
- Use contraception reliably; men note semen may pose risks.
- Avoid pregnancy; stop bosentan if pregnant.
Lifestyle: Maintain exercise as tolerated, follow low-salt diet if edema-prone, and report new symptoms promptly.
Common side effects
Most side effects are manageable. Here’s a table of common ones and coping strategies:
| Side Effect | What to Do |
|---|---|
| Headache | Drink water; use pharmacist-recommended painkiller. See doctor if persistent. |
| Swollen feet/ankles (edema) | Speak to doctor if troublesome; elevate legs. |
| Dizziness/faintness | Avoid driving/tools; rise slowly. |
| Gastric reflux/diarrhea | Eat simple meals, avoid spicy/fatty foods, stay hydrated. |
| Palpitations, flushing, stuffy nose | Speak to doctor if bothersome. |
| Itchy rash | Contact doctor promptly. |
| Blood test changes (e.g., low hemoglobin) | Doctor monitors routinely. |
Serious risks: Liver failure (1-2% risk, higher early on), pulmonary edema (check for veno-occlusive disease), fetal harm, blood clots, anemia>. Post-marketing: Fluid retention, heart failure worsening in systolic dysfunction.
Less common side effects
- Hypersensitivity: Rash, itching, anaphylaxis – stop and seek help.
- Thrombocytopenia or leukopenia.
- Testosterone suppression in men (monitor).
- Pulmonary veno-occlusive disease signs (edema) – discontinue.
Seek immediate care for severe symptoms. Full list in product information.
Frequently Asked Questions (FAQs)
Q: Can I take bosentan with food?
A: Yes, with or without food. Swallow whole with water.
Q: How often are liver tests needed?
A: Monthly for first year, then quarterly; more if enzymes rise.
Q: Is bosentan safe in pregnancy?
A: No – absolutely contraindicated. Use contraception; monthly tests required.
Q: What if I miss a dose?
A: Take promptly unless near next; skip double-dosing.
Q: Does bosentan cure PAH?
A: No, it manages symptoms and improves capacity but doesn’t cure.
Q: Can children take it?
A: Yes, for PAH in ages ≥3; dose by weight.
References
- Stayveer | European Medicines Agency (EMA) — EMA. 2023. https://www.ema.europa.eu/en/medicines/human/EPAR/stayveer
- Bosentan tablets – Stayveer | Patient.info — Patient.info. 2024-01-13. https://patient.info/medicine/bosentan-tablets-stayveer
- Stayveer EPAR Product Information — EMA. 2023-05-15. https://www.ema.europa.eu/en/documents/product-information/stayveer-epar-product-information_en.pdf
- Bosentan: MedlinePlus Drug Information — U.S. National Library of Medicine. 2025-06-01. https://medlineplus.gov/druginfo/meds/a605001.html
- Bosentan (oral route) – Mayo Clinic — Mayo Clinic. 2025-03-20. https://www.mayoclinic.org/drugs-supplements/bosentan-oral-route/description/drg-20068086
- Bosentan: Uses, Interactions | DrugBank — DrugBank. 2025-11-10. https://go.drugbank.com/drugs/DB00559



